St. Louis, MO 10/3/14—Sigma-Aldrich has agreed to acquire Cell Marque for an undisclosed amount. Cell Marque designs, develops and manufactures antibody reagents and kits for immunohistochemistry. “We expect that Cell Marque’s strong in vitro diagnostic (IVD) antibody product lines and solid relationships with pathologists and companies that provide automated staining instrumentation will broaden the diagnostic-health […]
develop companion diagnostics. Thermo Fisher Scientific on September 25 announced a partnership with GlaxoSmithKline and Pfizer to develop an NGS oncology test for solid tumors. The test will be used as a companion diagnostic for several drug programs after premarket approval from the FDA and other regulatory agencies. The test will apply to CNVs, gene […]
Company Announcements For the fiscal first quarter ending June 30, Hitachi High-Technologies Science and Medical Systems (SMS) sales climbed 33% to ¥38.8 billion ($380.1 million = ¥102.09 = $1) to account for 25% of company revenues (see IBO 7/31/14). Medical product sales jumped 53%, and sales of Biotechnology and Other products grew 16% to account […]
PerkinElmer has launched the AlphaPlex reagent technology for multiplex immunoassay analysis. AlphaPlex is based on the company’s Alpha (amplified luminescence proximity homogenous assays) technology, a homogeneous, bead-based, no-wash assay platform. Alpha Technology offerings also include the AlphaLISA and AlphaScreen reagents. Based on the transfer of energy between Donor and Acceptor beads, AlphaPlex can generate multiple […]
San Diego, CA 8/21/14; London, England 8/21/14—Illumina has formed collaborative partnerships with AstraZeneca, Janssen Biotech and Sanofi to develop a universal next-generation sequencing (NGS)–based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multigene panel for therapeutic selection. The partnership involves […]
As part of its move into the clinical market, Illumina has formed a collaboration with pharmaceutical companies AstraZeneca, Janssen Biotech and Sanofi to develop a companion-diagnostic test for oncology based on next-generation sequencing (NGS) (see page 2). Intending to extend the partnership to additional companies, Illumina plans to develop the Universal Oncology Test System, to […]
Company Announcements In May, QIAGEN cofounder Dr. Detlev Riesner stepped down from the Supervisory Board. Dr. Elaine Mardis, codirector of the Genome Institute at Washington University and the Robert E. and Louise F. Dunn Distinguished Professor of Medicine, was proposed as a new member. Endress+Hauser revenues rose over 7% in 2013 to €1.8 billion ($2.4 […]
San Diego, CA 7/16/14—Illumina has purchased Myraqa, a regulatory and quality consulting firm that specializes in IVD, particularly companion diagnostics. The purchase price was undisclosed. Illumina stated that the acquisition adds to its in-house capabilities for clinical readiness and prepares it for its next growth phase in regulated markets. “With Myraqa, Illumina will continue to […]
Hercules, CA 4/10/14; Cambridge, MA 4/10/14—Bio-Rad Laboratories, a provider of products for clinical diagnostics and life science research, has acquired Cambridge, Massachusetts–based GnuBIO, for an undisclosed amount. GnuBIO is the developer of a low-cost, droplet-based, integrated sequencing system that delivers results in hours rather than days. The instrument handles target selection, amplification, sequencing and informatics […]
At a time when large exhibitions seem to be declining in attendance and exhibitor participation, Analytica has clearly established itself as a “must-attend event” based on a proven formula for success. The trade fair took place May 10–13 in Munich, Germany. Held at an outstanding modern venue in the heart of Europe, well planned and […]
Pay Invoice
Latest Blogs
-
Lab Instrument Sales in China Collapse
March 29, 2024 1:15 pm
-
Pittcon 2024 Comes to San Diego
February 14, 2024 1:10 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
